Safety and efficacy of fecal microbiota transplantation in solid cancers resistant to immune checkpoint inhibitors: results of the MITRIC trial.
Reconstituting gut bacteria from immune responders appears safe and shows early promise for helping immunotherapy-resistant cancer patients respond to treatment.
The MITRIC Phase II trial assessed FMT from immune responder donors in ICI-resistant solid cancer patients, evaluating whether gut microbiome reconstitution could restore immunotherapy sensitivity. Results demonstrated favorable safety and early efficacy signals, supporting continued investigation of microbiome modulation to overcome ICI resistance.
What the study was
- Study design
- Phase II clinical trial
- Category
- Other
- Maturity
- Validated
- Journal
- J Immunother Cancer
Why it surfaced
Phase II RCT-grade clinical trial of FMT to overcome ICI resistance; novel microbiome-immunotherapy axis; high unmet need; J Immunother Cancer.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.